By Cameron Chai
A developer of nanomaterials for antiviral therapy, NanoViricides has stated that the company is financially stable and equipped with resources to enhance its drug product line by its first IND submission to the FDA.
Recently, NanoViricides had reported that the post-infection treatment performed using three different kinds of FluCide drug agents resulted in the survival of animals during the study period. The drugs enabled more than 95% reduction in necrosis and lung inflammation as well as more than 1000-fold decrease of viral load in the animals’ lungs that were infected with fatal dosage of influenza virus. Thus, the company hopes that the FluCide program is used for further development with respect to IND submission.
Also, the company has declared that its present HIVCide drug candidate was equivalent to the HAART triple drug cocktail of HIV-resistant drugs in a typical humanized mouse model known as SCID hu-Thy/Liv mouse model. This study was performed to find an anti-HIV nanoviricide ligand that is better than previously used ligands as well as to validate past study results.
At present, NanoViricides includes five key candidates in its drug pipeline such as DengueCide, HerpiCide, HIVCide, FluCide, and a wide-spectrum of nanoviricide eye drops for treating eyes’ viral infections. These programs are solely based on NanoViricides’ technology that allows targeting a specific kind of virus. Further, the company is working on other research and development programs including its unique accurate drug in field (ADIF) technologies which aim to attack new viruses, irrespective of its source either natural such as SARS or man-made, before causing a pandemic, as well as wide-spectrum nanoviricides against several neglected tropical diseases.